Click to go to DrugInjuryLaw Home


Legal information and news about prescription drug side effects
NuvaRing Case Evaluation Ortho Evra Case Evaluation Fosamax Case Evaluation Avandia Case EvaluationKetek Case Evaluation Zelnorm Case Evaluation Meridia Case Evaluation Zocor Case Evaluation
Vytorin Case EvaluationZetia Case Evaluation Yasmin Case Evaluation Ocella Case EvaluationYAZ Case Evaluation Levaquin Case Evaluation Byetta Case Evaluation Gianvi Case Evaluation


Free Case Evaluation

In 2009 Bayer Was Required To Correct Advertising Information About Benefits And Risks Of Its YAZ Birth Control Pill

Similarly, In 2003 The FDA Sent A Warning Letter To Berlex Laboratories Regarding Yasmin Ads That Regulators Said Minimized Safety Issues

YAZ has become the best-selling oral contraception pill in the U.S. according to IMS Health, with about 18 percent of the market share; its 2008 sales revenue was about $616 million. YAZ is manufactured and marketed by Bayer Healthcare Pharmaceuticals.

From early February 2009 to late July 2009, however, the Food and Drug Administration (FDA) and the attorneys general of 27 states have required Bayer to run a $20 million advertising campaign for the purpose of correcting previous YAZ marketing statements. In addition, for the next six years Bayer must submit all YAZ ads to the FDA screening before they appear.

Essentially, Bayer's earlier YAZ ads allegedly overstated the pill's ability to improve women’s moods and clear up acne, while playing down its potential serious side effect risks. The FDA first took action against Bayer as concerns these earlier misleading YAZ ads in October 2008 when the agency sent a warning letter to Bayer saying that two television ads overstated the drug’s benefits while understating its risks.

Let's start with that part of the 2008 FDA warning letter that says Bayer overstated the benefits of YAZ. The FDA asserted that Bayer's earlier ads tended to give consumers the impression that YAZ was a drug for acne and general mood problems. When the FDA initially approved YAZ in 2006 it was approved as a birth control pill that has a side benefit in treating a very specific mood-related psychological problem called "premenstrual dysphoric disorder". In 2007 the agency approved another side benefit of YAZ, which is improving moderate acne. However, YAZ has never been approved for simple acne and general mood problems; therefore, Bayer’s YAZ ads violated federal laws that prohibit a drug company from promoting the unapproved uses of a drug, the FDA said in its October 2008 YAZ warning letter.

Next, we consider the potential health risks of YAZ which -- according to the 27 state attorneys general and the FDA -- Bayer allegedly minimized or understated. YAZ contains drospirenone (DRSP), a relatively new progestin that can cause serious side effects involving the formation of dangerous blood clots in some patients. In particular, the use of YAZ has been associated with pulmonary embolisms (PE) and deep vein thrombosis (DVT) as well as strokes, heart attacks, and sudden death.

Interestingly, another birth control pill which closely resembles YAZ, Yasmin -- both contain contain ethinyl estradiol and the new "fourth generation" progestin drospirenone (DRSP) -- had been the subject of a similar FDA warning letter back in 2003. This Yasmin FDA warning letter was sent to Berlex Laboratories; Bayer acquired Berlex as part of a deal in 2006, and Bayer now markets Yasmin. According to IMS Health, in 2008 Yasmin had sales of about $382 million, or about 11 percent of the U.S. market.

Go to Free Case Evaluation form >>

Read more on our Drospirenone (DRSP) Birth Control Pills Information Page >>


  • US FDA advises that you should not stop taking any prescription medication before talking to your doctor.
  • Reports of serious drug side effects should be made to the US FDA MedWatch program.
  • The prescription drug names are registered trademarks of the respective drug companies.
  • DrugInjuryLaw.com is not affiliated with any of the drug companies, nor US FDA.
Law Offices of Thomas J. Lamb, P.A.
Lumina Station Suite 225
1908 Eastwood Road
Wilmington, NC 28403
Tel: (910) 256-2971   Fax: (910) 256-2972
Toll Free: (800) 426-9535
email: ThomasJLamb@DrugInjuryLaw.com

Disclaimer